Hypertension is a medical condition it is characterized by elevated blood pressure in arteries due to high pressure it becomes harder for heart to pump this can ultimately leads to stoke, myocardial infraction, chronic kidney disease, and heart failure. Hypertension is a major risk factor for progression of kidney function, resulting in end-stage renal disease (ESRD). CKD in return, has an adverse effect on blood pressure and may leads to refractory hypertension and along with increased in proteinuria. The blood pressure can reduce the progression of the CKD and also cardiovascular risk. Calcium-channel blockers (CCBs) were considered first-line medication for both hypertension and CKD patients as they being potent vasodilators, are particularly effective in reducing peripheral resistance. Among the CCB’s comparison between the cilnidipine and amlodipine, cilnidipine shows the more additional therapeutical effect in decreasing of blood pressure along with proteinuria when compared with amlodipine which is mandatory in hypertension with CKD patients. Amlodipine acts on L-type calcium channel to reduce the blood pressure but it also increases the intraglomerular pressure causing the peripheral oedema where cilnidipine acts on both L-type and N-type calcium channel it helps to reduces the blood pressure by decrease the peripheral resistance and also reduces the intraglomerular pressure that helps to in reduction of peripheral oedema respectively by resisting sympathetic activity which leads inhibition of release of nor-epinephrine .These article explains the effective drug of choice in CCB’s. Among amlodipine and cilnidipine, cilnidipine has more incidence in reducing proteinuria than amlodipine.